Arcturus Therapeutics Holdings Inc

NASDAQ:ARCT   3:59:14 PM EDT
50.05
+0.68 (+1.38%)
Products

Arcturus Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810

Published: 10/05/2020 17:17 GMT
Arcturus Therapeutics Ltd (ARCT) - Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of Arct-810, Therapeutic Candidate for Ornithine Transcarbamylase (otc) Deficiency.
Arcturus Therapeutics Holdings - Initial Dosing of Otc-deficient Patients at a U.S. Clinical Site Expected in Q4.
Arcturus Therapeutics Holdings - Arct-810 Well Tolerated at Doses Up to 0.3 Mg/kg, 0.4 Mg/kg Cohort to Be Completed in Q4.
Arcturus Therapeutics Holdings - Arct-810 Demonstrated Favorable Pharmacokinetic Profile.
Arcturus Therapeutics Holdings - No Arct-810 Lipid Detectable in Plasma Beyond 48 Hours Following Drug Administration.